Skip to content

Trial Summary

The main aim of this Phase I study is to assess the safety and immune effects of using autologous peripheral blood T cells in GD2 positive patients being treated with vemurafenib.

Acronym:

CARPETS

ACTRN/NCT /ethics:

ACTRN12613000198729

Scientific title:

Study of increasing doses of genetically modified GD2-specific T cells in patients with metastatic melanoma and refractory solid tumours

Sponsor / Cooperative group:

CALHN

Trial & Patient Characteristics

Cancer TypeAll cancers; Melanoma & other skin
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2013-03-29
Anticipated End Date-

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorProfessor Michael Brown
Recruitment StatusRecruitment on hold
HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal Investigator-
Recruitment StatusRecruiting